Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

Infectious Diseases and Therapy

Volumn 5, Issue 4, 2016, Pages 417-452

  Figueras Aloy, Josep ^a   Manzoni, Paolo ^b   Paes, Bosco ^c   Simões, Eric A F ^d   Bont, Louis ^e   Checchia, Paul A ^f   Fauroux, Brigitte ^g   Carbonell Estrany, Xavier ^h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Sant'Anna Hospital   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

Burden; Gestational age; Hospitalization; Immunoprophylaxis; Preterm; Respiratory syncytial virus; Risk

Indexed keywords

BRONCHIOLITIS; CHRONIC LUNG DISEASE; CLINICAL ASSESSMENT; CONGENITAL HEART DISEASE; DISEASE PREDISPOSITION; GESTATIONAL AGE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW;

EID: 84997751386     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-016-0130-1     Document Type: Review

References (100)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–6.
3. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–98.
4. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341–8.
5. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865–70.
6. Resch B. Respiratory syncytial virus infection in high-risk infants—an update on palivizumab prophylaxis. Open Microbiol J. 2014;11:71–7.
7. Figueras-Aloy J, Carbonell-Estrany X, Quero J, for the IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815–20.
8. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabanās J, Echaniz-Urcelay I, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788–93.
9. Law BJ, Langley JM, Allen U, Paes B, Lee DSC, Mitchell M, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23:806–14.
10. Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, on behalf of the Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013;8:e59161.
11. Korsten K, Blanken MO, Nibbelke EE, Moons KGM, Bont L, On behalf of the Dutch RSV Neonatal Network. Prediction model of RSV-hospitalization in late preterm infants: an update and validation study. Early Hum Dev. 2016;95:35–40.
12. Straňák Z, Saliba E, Kosma P, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS ONE. 2016;11:e0157446.
13. World Health Organization. Born too soon: The Global Action Report on Preterm Birth. 2012. http://apps.who.int/iris/bitstream/10665/44864/1/9789241503433_eng.pdf?ua=1. Accessed May 2016.
14. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143:S133–41.
15. Carbonell-Estrany X, Pérez-Yarza EG, García LS, Cabañas JMG, Bòria EV, Atienza BB, IRIS Study Group. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-the SPRING study. PLoS One. 2015;10:e0125422.
16. Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171:1055–61.
17. Greenough A, Broughton S. Chronic manifestations of respiratory syncytial virus infection in premature infants. Pediatr Infect Dis J. 2005;24:S184–7.
18. Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, et al. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax. 2005;60:1039–44.
19. Drysdale SB, Alcazar-Paris M, Wilson T, Smith M, Zuckerman M, Peacock JL, et al. Viral lower respiratory tract infections and preterm infants’ healthcare utilisation. Eur J Pediatr. 2015;174:209–15.
20. Mauskopf J, Margulis AV, Samuel M, Lohr KN. Respiratory syncytial virus hospitalizations in healthy preterm infants: systematic review. Pediatr Infect Dis J. 2016;35:e229–38.
21. American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Edition. Editor: Larry K. Pickering, MD, FAAP; Associate Editors: Carol J. Baker, MD, FAAP; David W. Kimberlin, MD, FAAP; Sarah S. Long, MD, FAAP.
22. Samson L, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Prevention of respiratory syncytial virus infection. Paediatr Child Health. 2009;14:521–32.
23. Figueras-Aloy J, Carbonell-Estrany X, Comité de Estándares de la SENeo. Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial. An Pediatr. 2015;82:199.e1–2.
24. Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, Italian Society of Neonatology, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital. J Pediatr. 2015;41:97.
25. Bont L, Checchia P, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infect Dis Ther. 2016. (Epub ahead of print).
26. OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed Mar 2016.
27. OCEBM Levels of Evidence Working Group. “The Oxford 2009 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed Mar 2016.
28. Viswanathan M, Berkman ND, Dryden DM, L Hartling. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Methods Research Report. AHRQ Publication No. 13-EHC106-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed Mar 2016.
29. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993–2000: a population-based retrospective study. BMC Pediatr. 2004;4:25.
30. Hervás D, Reina J, Yañez A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis. 2012;31:1975–81.
31. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003;88:1065–9.
32. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212–9.
33. Handal G, Logvinoff MM, Zegarra N, Allen L, Jesurun A, Levin G, et al. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection. Tex Med. 2000;96:58–61.
34. Corsello G, Di Carlo P, Salsa L, Gabriele B, Meli L, Bruno S, et al. Respiratory syncytial virus infection in a Sicilian pediatric population: risk factors, epidemiology, and severity. Allergy Asthma Proc. 2008;29:205–10.
35. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000;83:313–6.
36. Nielsen HE, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst CH, Nørgaard-Pedersen B, et al. Respiratory syncytial virus infection—risk factors for hospital admission: a case-control study. Acta Paediatr. 2003;92:1314–21.
37. Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, Pérez-Yarza E, et al. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country. Spain. Epidemiol Infect. 2006;134:506–13.
38. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti U, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007;166:1267–72.
39. Garcia CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010;126:e1453–60.
40. Forster J, Schumacher RF. The clinical picture presented by premature neonates infected with the respiratory syncytial virus. Eur J Pediatr. 1995;154:901–5.
41. Olabarrieta I, Gonzalez-Carrasco E, Calvo C, Pozo F, Casas I, García-García ML. Hospital admission due to respiratory viral infections in moderate preterm, late preterm and term infants during their first year of life. Allergol Immunopathol (Madr). 2015;43:469–73.
42. Lanari M, Giovannini M, Giuffré L, Marini A, Rondini G, Rossi GE, the Investigators R.A.DA.R. Study Group, et al. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol. 2002;33:458–65.
43. Gijtenbeek RG, Kerstjens JM, Reijneveld SA, Duiverman EJ, Bos AF, Vrijlandt E. RSV infection among children born moderately preterm in a community-based cohort. Eur J Pediatr. 2015;174:435–42.
44. Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O. Hospital admission of high risk infants from respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F64–8.
45. Pedersen O, Herskind AM, Kamper J, Nielsen JP, Kristensen K. Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark. Acta Paediatr. 2003;92:240–2.
46. Van de Steen O, Miri F, Gunjaca M, Klepac V, Gross B, Notario G, et al. The burden of severe respiratory syncytial virus disease among children younger than 1 year in Central and Eastern Europe. Infect Dis Ther. 2016;5:125–37.
47. Eriksson M, Bennet R, Rotzén-Östlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91:593–8.
48. Haerskjold A, Kristensen K, Kamper-Jørgensen M, Nybo Andersen A-M, Ravn H, Stensballe LG. Risk factors for hospitalization for respiratory syncytial virus infection: a population-based cohort study of Danish children. Pediatr Infect Dis J. 2016;35:61–5.
49. Helfrich AM, Nylund CM, Eberly MD, Eide MB, Stagliano DR. Healthy Late-preterm infants born 33–36 + 6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev. 2015;91:541–6.
50. Gouyon JB, Rozé JC, Guillermet-Fromentin C, Glorieux I, Adamon L, Di Maio M, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect. 2013;141:816–26.
51. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165:498–505.
52. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J. 2000;19:592–7.
53. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874–9.
54. Lanari M, Adorni F, Silvestri M, Coscia A, Musicco M, Italian Study Group on Risk Factors for RSV-related Hospitalization. The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33 weeks GA or more: preliminary results. Early Hum Dev. 2011;87:S43–6.
55. Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks’ gestational age. Pediatr Infect Dis J. 2006;25:1188–90.
56. Resch B, Gusenleitner W, Müller WD, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis. 2006;25:120–2.
57. Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32–35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014;33:576–82.
58. Winterstein AG, Knox CA, Kubilis P, Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study. JAMA Pediatr. 2013;167:1118–24.
59. Pezzotti P, Mantovani J, Benincori N, Mucchino E, Di Lallo D. Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy. BMC Pediatr. 2009;9:56.
60. Silvestri M, Marando F, Costanzo AM, di Luzio Paparatti U, Rossi GA. Respiratory syncytial virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study. Ital J Pediatr. 2016;42:40.
61. Carbonell X, Fullarton JR, Gooch KL, Figueras-Aloy J. The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32–35 weeks’ gestational age: time-based analysis using data from the FLIP-2 study. J Perinat Med. 2012;40:685–91.
62. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, RSV Munich Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162:230–6.
63. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999;104:894–9.
64. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143:S150–6.
65. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55–61.
66. Piñero Fernández JA, Alfayate Migueléz S, Menasalvas Ruiz A, Salvador García C, Moreno Docón A, Sánchez-Solís de Querol M. Epidemiology, clinical features and medical interventions in children hospitalized for bronchiolitis. An Pediatr (Barc). 2012;77:391–6.
67. López Guinea A, Casado Flores J, Martín Sobrino MA, Espínola Docio B, de la Calle Cabrera T, Serrano A, et al. Severe bronchiolitis. Epidemiology and clinical course of 284 patients. An Pediatr (Barc). 2007;67:116–22.
68. Bergsträsser E, Zbinden R, Minder C, Gnehm HE. Severity of respiratory syncytial virus infection influenced by clinical risk factors and subtype A and B in hospitalized children. Klin Padiatr. 1998;210:418–21.
69. Papenburg J, Hamelin MÈ, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis. 2012;206:178–89.
70. Bonillo Perales A, DíezDelgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria M, Batlles Garrido J, et al. Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group. An Esp Pediatr. 2000;53:527–32.
71. Grimaldi M, Cornet B, Milou C, Gouyon JB. Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis. Arch Pediatr. 2002;9:572–80.
72. Tsolia MN, Kafetzis D, Danelatou K, et al. Epidemiology of respiratory syncytial virus bronchiolitis in hospitalized infants in Greece. Eur J Epidemiol. 2003;18:55–61.
73. Simon A, Müller A, Khurana K, Engelhart S, Exner M, Schildgen O, DSM RSV Paed Study Group, et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection—results from a prospective multicenter German surveillance. Int J Hyg Environ Health. 2008;211:241–50.
74. Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EAF, et al. SENTINEL 1: an observational study of respiratory syncytial virus hospitalizations among US infants born at 29–35 weeks’ gestational age not receiving immunoprophylaxis. Am J Perin. 2016. (Epub ahead of print).
75. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003;143:S142–9.
76. Pruikkonen H, Uhari M, Dunder T, Pokka T, Renko M. Infants under 6 months with bronchiolitis are most likely to need major medical interventions in the 5 days after onset. Acta Paediatr. 2014;103:1089–93.
77. Sala KA, Moore A, Desai S, Welch K, Bhandari S, Carroll CL. Factors associated with disease severity in children with bronchiolitis. J Asthma. 2015;52:268–72.
78. Simões EA, Ambrose CS, Wu X, Anderson EJ. Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32–35 week gestation and not receiving immunoprophylaxis. Pediatr Infect Dis J. 2015;34:331.
79. Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol. 2007;27:614–9.
80. Bala P, Ryan CA, Murphy BP. Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F92.
81. Krilov LR, Halasa N, Thomas NJ, Anderson EJ, Pannaraj PS, Forbes ML, et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among United States infants born at 29–35 weeks’ gestational age not receiving immunoprophylaxis. In: Poster presented at: 113th Annual National Medical Association Convention and Scientific Assembly; August 1–5, 2015; Detroit.
82. Stewart DL, Romero JR, Buysman EK, Fernandes AW, Mahadevia PJ. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin. 2009;25:2795–804.
83. Rietveld E, De Jonge HCC, Polder JJ, Vergouwe Y, Veeze HJ, Moll HA, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J. 2004;23:523–9.
84. Leader S, Yang H, DeVincenzo J, Jacobson P, Marcin JP, Murray DL. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health. 2003;6:100–6.
85. Makari D, Hoopes JM, White N. Impact of RSV: implications for managed care. Manag Care. 2009;18:2–7.
86. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143:S127–32.
87. Leidy NK, Margolis MK, Marcin JP, Flynn JA, Frankel LR, Johnson S, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics. 2005;115:1536–46.
88. Méndez Rubio I, Lázaro de Mercado P, Carbonell Estrany X, Figueras Aloy J, Grupo IRIS. Quality of life of preterm infants and admissions due to respiratory infections. An Pediatr (Barc). 2010;73:121–31.
89. Lanari M, Prinelli F, Adorni F, Di Santo S, Faldella G, Silvestri M, Italian Neonatology Study Group on RSV Infections, et al. Maternal milk protects infants against bronchiolitis during the first year of life. Results from an Italian cohort of newborns. Early Hum Dev. 2013;89:S51–7.
90. Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, et al. Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis. J Matern Fetal Neonatal Med. 2013;26:926–31.
91. Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, European RSV Risk Factor Study Group, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9:78.
92. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O’Brien K, Allen U, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008;28:471–80.
93. Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E, Grupo IRIS. Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain. An Pediatr (Barc). 2009;71:47–53.
94. Brubaker PH. Do not be statistically cenophobic: time to roc and roll! J Cardiopulm Rehabil Prev. 2008;28:420–1.
95. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, European RSV, Risk Factor Study Group. European risk factors’ model to predict hospitalization of premature infants born 33–35 weeks’ gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med. 2011;24:152–7.
96. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J. 2010;29:374–6.
97. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB, European RSV, Risk Factor Study Group. Validation of a model to predict hospitalization due to RSV of infants born at 33–35 weeks’ gestation. J Perinat Med. 2010;38:411–7.
98. Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada. Curr Med Res Opin. 2009;25:1585–91.
99. Sheridan-Pereira M, Murphy J, Sloan J, Crispino G, Leahy A, Corcoron JD, et al. Respiratory syncytial virus preterm (32–36 completed weeks gestation) risk estimation measure for RSV hospitalisation in Ireland: a prospective study. Pediatr Infect Dis J. 2016;35:19–24.
100. Alan S, Erdeve O, Cakir U, Akduman H, Zenciroglu A, Akcakus M, et al. Outcome of the respiratory syncytial virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study. J Matern Fetal Neonatal Med. 2016;29:2186–93.